Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%

benzinga.com/general/biotech/25/05/45676544/keros-therapeutics-stops-pah-drug-development-shrinks-workforce-by-45

Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (PAH) on Wednesday.
In December 2024, the company voluntarily halted the 3.0 mg/kg and…

This story appeared on benzinga.com, 2025-05-29 16:54:09.
The Entire Business World on a Single Page. Free to Use →